These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 36112771)

  • 21. First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma.
    Duan X; Xia L; Zhang Z; Ren Y; Pomper MG; Rowe SP; Li X; Li N; Zhang N; Zhu H; Yang Z; Sheng X; Yang X
    Clin Cancer Res; 2023 Sep; 29(17):3395-3407. PubMed ID: 37093191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enfortumab vedotin to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption.
    Hasegawa T; Oyama N; Kasamatsu H; Chino T; Taga M; Hasegawa M
    J Dermatol; 2022 Dec; 49(12):e453-e454. PubMed ID: 36052729
    [No Abstract]   [Full Text] [Related]  

  • 25. Enfortumab vedotin in the treatment of urothelial cancers and beyond.
    Wong RL; Yu EY
    Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nectin-4 is widely expressed in head and neck squamous cell carcinoma.
    Sanders C; Lau JF; Dietrich D; Strieth S; Brossart P; Kristiansen G
    Oncotarget; 2022 Oct; 13():1166-1173. PubMed ID: 36268557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review.
    Bouleftour W; Guillot A; Magne N
    Mol Cancer Ther; 2022 Apr; 21(4):493-501. PubMed ID: 35131876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
    Aggen DH; Chu CE; Rosenberg JE
    Clin Cancer Res; 2023 Apr; 29(8):1377-1380. PubMed ID: 36749325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.
    Ghali F; Vakar-Lopez F; Roudier MP; Garcia J; Arora S; Cheng HH; Schweizer MT; Haffner MC; Lee JK; Yu EY; Grivas P; Montgomery B; Hsieh AC; Wright JL; Lam HM
    Clin Genitourin Cancer; 2023 Dec; 21(6):669-678. PubMed ID: 37344281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
    Penny CL; Quow K; Rundle CW; Al-Rohil RN; Cardones AR; Kheterpal MK; Fresco AI
    Br J Dermatol; 2022 Jul; 187(1):126-127. PubMed ID: 35048357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?
    Filippi L; Schillaci O
    Expert Rev Anticancer Ther; 2024; 24(1-2):1-4. PubMed ID: 37994866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
    Bahlinger V; Branz A; Strissel PL; Strick R; Lange F; Geppert CI; Klümper N; Hölzel M; Wach S; Taubert H; Sikic D; Wullich B; Angeloni M; Ferrazzi F; Diehl L; Kovalenko M; Elboudwarej E; Jürgensmeier JM; Hartmann A; Eckstein M
    Histopathology; 2024 Apr; 84(5):863-876. PubMed ID: 38196202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
    Chou J; Trepka K; Sjöström M; Egusa EA; Chu CE; Zhu J; Chan E; Gibb EA; Badura ML; Contreras-Sanz A; Stohr BA; Meng MV; Pruthi RS; Lotan Y; Black PC; Porten SP; Koshkin VS; Friedlander TW; Feng FY
    Eur Urol Oncol; 2022 Dec; 5(6):714-718. PubMed ID: 35216942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin.
    Fahey CC; Nebhan CA; York S; Davis NB; Hurley PJ; Gordetsky JB; Schaffer KR
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with
    Zhang J; Duan X; Chen X; Zhang Z; Sun H; Shou J; Zhao G; Wang J; Ma Y; Yang Y; Tian X; Shen Q; Yu W; He Z; Fan Y; Yang X
    J Nucl Med; 2024 May; 65(Suppl 1):12S-18S. PubMed ID: 38719240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin.
    Cho WC; Saade R; Nagarajan P; Aung PP; Milton DR; Marques-Piubelli ML; Hudgens C; Ledesma D; Nelson K; Ivan D; Zhang M; Torres-Cabala CA; Campbell M; Alhalabi O; Prieto VG; Wistuba II; Esmaeli B; Curry JL
    J Cutan Pathol; 2024 May; 51(5):360-367. PubMed ID: 38200650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
    Heath EI; Rosenberg JE
    Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The emerging role of antibody-drug conjugates in urothelial carcinoma.
    Lattanzi M; Rosenberg JE
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
    Rosenberg J; Sridhar SS; Zhang J; Smith D; Ruether D; Flaig TW; Baranda J; Lang J; Plimack ER; Sangha R; Heath EI; Merchan J; Quinn DI; Srinivas S; Milowsky M; Wu C; Gartner EM; Zuo P; Melhem-Bertrandt A; Petrylak DP
    J Clin Oncol; 2020 Apr; 38(10):1041-1049. PubMed ID: 32031899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Significance of Nectins in HCC and Other Solid Malignant Tumors: Implications for Prognosis and New Treatment Opportunities-A Systematic Review.
    Klekowski J; Zielińska D; Hofman A; Zajdel N; Gajdzis P; Chabowski M
    Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.